SAVA – cassava sciences, inc. (US:NASDAQ)

News

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Cassava Sciences, Inc. (NASDAQ: SAVA) had its price target raised by analysts at HC Wainwright from $124.00 to $131.00. They now have a "buy" rating on the stock.
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam [Yahoo! Finance]
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com